PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35561128-11	2022	In conclusion, bisphosphonate use, especially persistence to intravenous bisphosphonates (e.g., zoledronic acid), may reduce post-fracture mortality among osteoporosis patients, particularly those with hip/vertebral fractures.	Diphosphonates	15-29	hedgehog interacting protein	Homo sapiens	202-205	
31828096-6	2019	Overall in the pairwise meta-analyses, bisphosphonate use significantly reduced the risk of new vertebral, hip, and nonvertebral nonhip fractures, with ORs and 95% confidence intervals of 0.56 (0.49-0.64), 0.69 (0.48-0.98), and 0.82 (0.70-0.97), respectively.	Diphosphonates	39-53	hedgehog interacting protein	Homo sapiens	107-110	
29932001-0	2019	Locally administered bisphosphonate in hip stem revisions using the bone impaction grafting technique: a randomised, placebo-controlled study with DXA and five-year RSA follow-up.	Diphosphonates	21-35	hedgehog interacting protein	Homo sapiens	39-42	
21145521-13	2010	CONCLUSIONS: In this retrospective study, it was found that treatment with oral bisphosphonates significantly increases BMD at the hip in postpolio patients.	Diphosphonates	80-95	hedgehog interacting protein	Homo sapiens	131-134	
34920168-1	2022	Bisphosphonates are effective in reducing hip and other fractures.	Diphosphonates	0-15	hedgehog interacting protein	Homo sapiens	42-45	
34585781-0	2022	Total Hip Bone Mineral Density as an Indicator of Fracture Risk in Bisphosphonate-Treated Patients in a Real-World Setting.	Diphosphonates	67-81	hedgehog interacting protein	Homo sapiens	6-9	
34534754-3	2021	Bisphosphonates preserve bone mineral density at the hip but not at the knee, which is the anatomical site most prone to fracture in the SCI population.	Diphosphonates	0-15	hedgehog interacting protein	Homo sapiens	53-56	
33386876-2	2021	Our meta-analysis of studies shows that early bisphosphonate administration after SCI was safe and beneficial to the BMD of the total hip and lumbar spine at 12 months.	Diphosphonates	46-60	hedgehog interacting protein	Homo sapiens	134-137	
35279261-3	2022	Bisphosphonates are the most widely used anti-resorptives, reducing bone turnover markers to low premenopausal concentrations and reducing fracture rates (vertebral by 50-70%, non-vertebral by 20-30%, and hip by ~40%).	Diphosphonates	0-15	hedgehog interacting protein	Homo sapiens	205-208	
33386876-10	2021	RESULTS: There were significant differences in BMD of the total hip and lumbar spine or serum C-terminal telopeptide between the bisphosphonate and control groups but no difference in adverse events.	Diphosphonates	129-143	hedgehog interacting protein	Homo sapiens	64-67	
33386876-14	2021	CONCLUSION: Early bisphosphonate administration after SCI was safe and beneficial to the BMD of the total hip and lumbar spine at 12 months.	Diphosphonates	18-32	hedgehog interacting protein	Homo sapiens	106-109	
33479844-3	2021	In our population including 14,990 women and 13,239 men, use of bisphosphonates reduced risk of fractures in hip and forearm in women.	Diphosphonates	64-79	hedgehog interacting protein	Homo sapiens	109-112	
33479844-5	2021	INTRODUCTION: The objective was to examine if treatment with bisphosphonates (BPs) was associated with reduced risk of fractures in the hip and forearm in women and men in the general population.	Diphosphonates	61-76	hedgehog interacting protein	Homo sapiens	136-139	
33479844-5	2021	INTRODUCTION: The objective was to examine if treatment with bisphosphonates (BPs) was associated with reduced risk of fractures in the hip and forearm in women and men in the general population.	Diphosphonates	78-81	hedgehog interacting protein	Homo sapiens	136-139